ALL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allstate is not a strong buy right now for a Beginner investor focused on long-term holding. The stock has solid long-term business quality and a reliable dividend, but the current setup is mixed: technical momentum is weak, options sentiment is cautious, and the latest analyst opinions are split between bullish and neutral-to-negative views. Since the user is impatient and does not want to wait for a perfect entry, the current price is still not attractive enough to call it a direct buy. Best call: hold and wait for a better entry rather than buying immediately.
ALL is in a weak short-term trend. MACD histogram is -1.334 and negatively expanding, which points to bearish momentum. RSI_6 at 26.34 is near oversold territory, but the report labels it neutral, so there is no clean reversal signal yet. Moving averages are converging, suggesting the stock is not in a strong trend either way. Price at 207.2 is just below the pivot of 217.007 and near support at 209.224, with downside room to S2 at 204.415. The recent pattern forecast suggests a modest upside bias over time, but near-term momentum is still soft.
["Allstate declared a quarterly dividend of $1.08 per share, supporting shareholder returns.", "The company reported over 212 million policies in force, showing strong franchise scale and competitive position.", "Analyst targets from Keefe Bruyette, Piper Sandler, BofA, and Mizuho are all well above the current price, indicating meaningful upside potential in bullish models.", "Piper Sandler noted a beat versus estimates driven by better-than-expected favorable development.", "Some analyst sentiment remains constructive, with multiple Outperform/Overweight/Buy ratings still in place."]
["MACD is negative and worsening, signaling weak current momentum.", "The share price is trading below the pivot level and close to support, which leaves limited immediate upside confirmation.", "Goldman Sachs downgraded the stock to Neutral and cited concerns about market positioning, autonomous vehicle exposure, affordability, and premium growth.", "Barclays kept an Underweight rating and said premium growth and broker organic growth are likely to remain sluggish.", "Hedge funds and insiders are both neutral, with no strong recent buying trend.", "No AI Stock Pick or SwingMax buy signal is present today."]
Latest quarter financial data was not provided due to an error, so there is no direct quarter-by-quarter revenue or earnings snapshot available here. From the analyst commentary, the company appears to have produced a beat versus expectations, helped by favorable development, but top-line growth was lower than expected and PIF growth slowed versus the prior quarter even though auto PIF growth accelerated. For a long-term insurance name, the business remains fundamentally stable, but the latest growth trend looks mixed rather than strong.
Recent analyst trends are mixed but still lean constructive overall. Several firms raised targets: Keefe Bruyette to $266 with Outperform, Piper Sandler to $268 with Overweight, BofA to $297 with Buy, and Mizuho to $255 with Outperform. On the cautious side, Citi kept Neutral at $226, Barclays kept Underweight at $208, and Goldman downgraded to Neutral at $231. Wall Street’s bull case is centered on capital deployment, book value growth, favorable development, and dividend strength. The bear case is slower premium growth, weaker broker organic growth, valuation concerns, and exposure to changing industry dynamics. Overall, pros still outweigh cons on target prices, but the mixed ratings prevent this from being a strong immediate buy.
